granted a license from China Food and Drug Administration (CFDA) during the beginning of 2018 as the Company had to redesign and adjust product packaging according to the granted license as well as change
Consolidated financial statements Change Increase/(Decrease) For Three Months Period Ended 30 September 2017 2018 THB mm % THB mm % THB mm % Sale Revenue Revenue from selling product under Company’s trademark 1
–2021 Balance by Quarter Change Q2–21 Q1–21 Q2–20 Q2–21 VS Q1–21 Q2–21 VS Q2–20 (Million Baht: MB) (MB) % (MB) % Total revenue 2,081.2 1,824.2 1,187.6 257.0 14.1 893.6 75.2 Total operating expenses
change in net asset value (NAV). The returns do not reflect broker sales charges or commissions. NAV is total assets less total liabilities divided by the number of shares outstanding. This material is
change, depending upon the market price of the ordinary shares of the Company on the date which the Board of Directors determines the offering price of shares based on the market price which is the best
a trust, such person shall not have any of the following characteristics: (a) having a record of contravening a regulation or condition related to securities offering in a significant matter; (b
shall not have any of the following characteristics: (a) having a record of contravening a regulation or condition related to securities offering in a significant matter; (b) having been rejected by the
record of contravening a regulation or condition related to securities offering in a significant matter; (b) having been rejected by the SEC Office regarding an application for an offer for sale of newly
The financial expenses in 2017 were 16.91 million baht decreased from previous year which were at 7.77 million baht. Comparing in term of percent of revenues, the ratio is not much change. It was at